Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Double Voiding Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)

NCT00894465
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
midazolam, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 6 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling

NCT03913845
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
lidocaine with epinephrine, Normal saline with epinephrine
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
4
States / cities
Bethel Park, Pennsylvania • Jefferson Hills, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Efficacy Study of VA106483 in Males With Nocturia.

NCT01038843
View directory record Official record
Conditions
Nocturia
Interventions
VA106483
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 13, 2026, 2:50 AM EDT
Active, not recruiting Not applicable Interventional

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

NCT03522961
View directory record Official record
Conditions
Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions
Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Dose Range Finding Study of Fedovapagon in Men With Nocturia

NCT01656239
View directory record Official record
Conditions
Nocturia
Interventions
fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg, Placebo ( sugar pill)
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
55 Years and older · Male only
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Post-operative Urinary Retention

NCT02486653
View directory record Official record
Conditions
Urinary Retention, Urinary Tract Infections
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Interstitial Cystitis

NCT00056251
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
H&P; ECG; Blood tests; voiding diary; Cystoscopy
Procedure
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
24
States / cities
Anchorage, Alaska • Glendora, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

NCT01223937
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
41
States / cities
Huntsville, Alabama • Scottsdale, Arkansas • Foothill Ranch, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Suspended Not applicable Interventional

RF Ablation of the Trigone for the Treatment of UUI

NCT04408352
View directory record Official record
Conditions
Urgent Urinary Incontinence
Interventions
selective bladder denervation using RF energy
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
6
States / cities
Wichita, Kansas • Shreveport, Louisiana • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

Double Voiding and Post-transplant UTI

NCT05711446
View directory record Official record
Conditions
Urinary Tract Infections, Kidney Transplant; Complications
Interventions
Double Voiding, Regular Voiding
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 13, 2026, 2:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Over Active Bladder Patients Having Sling Surgery

NCT00852696
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin, Placebo
Drug · Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 13, 2026, 2:50 AM EDT
Completed No phase listed Observational

Brain Imaging in Men With Lower Urinary Tract Symptoms

NCT03991429
View directory record Official record
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 13, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

NCT06072703
View directory record Official record
Conditions
Neurogenic Bladder, Multiple Sclerosis, Overactive Bladder
Interventions
Magstim Rapid2 System
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

NCT01262456
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 13, 2026, 2:50 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin Succinate Suspension, Placebo, Urotherapy
Drug · Behavioral
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional

Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo

NCT01064024
View directory record Official record
Conditions
Pain, Urinary Tract Infections
Interventions
Phenazopyridine Hydrochloride, Placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Totowa, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Amplifying Sensation in Underactive Bladder

NCT04516434
View directory record Official record
Conditions
Urinary Bladder, Underactive
Interventions
Neurometer Neurotron CPT, Cystometry, Pressure-flow study
Device · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 13, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection

NCT01406587
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
PP4001, Placebo
Drug
Lead sponsor
Pinnacle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Sep 13, 2026, 2:50 AM EDT